Dihydroergotamine
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
pseudoephedrine
Sympathomimetic · Decongestant
SympathomimeticDecongestantATC R01BA02
CDSCO approvedATC R01BA02
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- DihydroergotamineSevereDatabaseDDInter
- ErgometrineSevereDatabaseDDInter
- Ergotamine TartrateSevereDatabaseDDInter
- IsocarboxazidSevereDatabaseDDInter
Mechanism
Not yet extracted
Indications
nasal congestionDecongestant of upper respiratory tract, nose, and eustachian tubes
Dosing
- Adult
- 30–60 mg TDS
Pharmacokinetics
Bioavailability
∼100%
Protein binding
—
Excretion
43–96%
Side effects
Serious
- Rise in BP (especially in hypertensives)
Drug interactions
Ergometrine
Severe
Database
Clinical effect not specified
Source: DDInter
Ergotamine Tartrate
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Isocarboxazid
Severe
Database
Clinical effect not specified
Source: DDInter
Linezolid
Severe
Database
Clinical effect not specified
Source: DDInter
Methylene Blue
Severe
Database
Clinical effect not specified
Source: DDInter
Methylergometrine
Severe
Database
Clinical effect not specified
Source: DDInter
Methysergide
Severe
Database
Clinical effect not specified
Source: DDInter
Ozanimod
Severe
Database
Clinical effect not specified
Source: DDInter
Phenelzine
Severe
Database
Clinical effect not specified
Source: DDInter
Procarbazine
Severe
Database
Clinical effect not specified
Source: DDInter
Selegiline
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Sympathomimetic drugs
Ask House about pseudoephedrine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team